inositol has been researched along with Cardiometabolic Syndrome in 20 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes." | 9.17 | Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. ( Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013) |
| "To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome." | 9.16 | One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. ( Benedetto, AD; Corrado, F; D'Anna, R; Giordano, D; Interdonato, ML; Pintaudi, B; Santamaria, A; Vieste, GD, 2012) |
| "The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women." | 9.15 | Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. ( Corrado, F; D'Anna, R; Di Benedetto, A; Giordano, D; Pintaudi, B; Quattrone, S; Santamaria, A, 2011) |
| "Inositols (INOs) supplementation during pregnancy, specifically the combination of myo-inositol (MI) and D-chiro-inositol (DCI), has been reported to improve vascular parameters in women with gestational diabetes mellitus." | 7.91 | Vascular and metabolic profiles in offspring born to pregnant mice with metabolic syndrome treated with inositols. ( Alrais, M; Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Refuerzo, JS; Sibai, BM; Tamayo, EH, 2019) |
| "Myoinositol and D-chiroinositol improve insulin resistance in women with obesity and gestational diabetes and in postmenopausal women with metabolic syndrome." | 7.83 | The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. ( Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Ontiveros, AE; Refuerzo, JS; Roberts, RP; Saade, MM; Sibai, BM, 2016) |
| "In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d-chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome." | 7.81 | Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. ( Benvenga, S; Bevilacqua, A; Bizzarri, M; Carlomagno, G; Cavalli, P; Chiu, TT; D'Anna, R; Devroey, P; Di Renzo, GC; Facchinetti, F; Gerli, S; Hod, M; Kamenov, ZA; Lanzone, A; Oliva, MM; Soulage, C, 2015) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 6.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes." | 5.17 | Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. ( Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013) |
| "To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome." | 5.16 | One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. ( Benedetto, AD; Corrado, F; D'Anna, R; Giordano, D; Interdonato, ML; Pintaudi, B; Santamaria, A; Vieste, GD, 2012) |
| " The effectiveness in reducing the risk of metabolic syndrome as well as in enhancing the ovarian functions of a combined therapy with MI and DCI was compared to a mono therapy in a randomized controlled trial." | 5.16 | The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. ( Nordio, M; Proietti, E, 2012) |
| "The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women." | 5.15 | Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. ( Corrado, F; D'Anna, R; Di Benedetto, A; Giordano, D; Pintaudi, B; Quattrone, S; Santamaria, A, 2011) |
| "Inositols (INOs) supplementation during pregnancy, specifically the combination of myo-inositol (MI) and D-chiro-inositol (DCI), has been reported to improve vascular parameters in women with gestational diabetes mellitus." | 3.91 | Vascular and metabolic profiles in offspring born to pregnant mice with metabolic syndrome treated with inositols. ( Alrais, M; Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Refuerzo, JS; Sibai, BM; Tamayo, EH, 2019) |
| "Myoinositol and D-chiroinositol improve insulin resistance in women with obesity and gestational diabetes and in postmenopausal women with metabolic syndrome." | 3.83 | The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. ( Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Ontiveros, AE; Refuerzo, JS; Roberts, RP; Saade, MM; Sibai, BM, 2016) |
| "To evaluate the effects of the combination of d-chiro-inositol (DCI) and alpha lipoic acid on menses and metabolic disorders in women with polycystic ovary syndrome (PCOS)." | 3.81 | d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. ( Bartolo, M; Caruso, S; Cianci, A; Falduzzi, C; Fichera, M; Panella, M, 2015) |
| "In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d-chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome." | 3.81 | Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. ( Benvenga, S; Bevilacqua, A; Bizzarri, M; Carlomagno, G; Cavalli, P; Chiu, TT; D'Anna, R; Devroey, P; Di Renzo, GC; Facchinetti, F; Gerli, S; Hod, M; Kamenov, ZA; Lanzone, A; Oliva, MM; Soulage, C, 2015) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 2.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonowski, T | 1 |
| Osowski, A | 1 |
| Lahuta, L | 1 |
| Górecki, R | 1 |
| Rynkiewicz, A | 1 |
| Wojtkiewicz, J | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Genazzani, A | 1 |
| Donnarumma, M | 1 |
| Marasca, C | 1 |
| Palma, M | 1 |
| Vastarella, M | 1 |
| Annunziata, MC | 1 |
| Fabbrocini, G | 1 |
| Longo, M | 2 |
| Alrais, M | 1 |
| Tamayo, EH | 1 |
| Ferrari, F | 2 |
| Facchinetti, F | 3 |
| Refuerzo, JS | 2 |
| Blackwell, SC | 2 |
| Sibai, BM | 2 |
| Croze, ML | 1 |
| Soulage, CO | 1 |
| Capasso, I | 1 |
| Esposito, E | 1 |
| Maurea, N | 1 |
| Montella, M | 1 |
| Crispo, A | 1 |
| De Laurentiis, M | 1 |
| D'Aiuto, M | 1 |
| Frasci, G | 1 |
| Botti, G | 1 |
| Grimaldi, M | 1 |
| Cavalcanti, E | 1 |
| Esposito, G | 1 |
| Fucito, A | 1 |
| Brillante, G | 1 |
| D'Aiuto, G | 1 |
| Ciliberto, G | 1 |
| Barberini, L | 1 |
| Noto, A | 1 |
| Fattuoni, C | 1 |
| Grapov, D | 1 |
| Casanova, A | 1 |
| Fenu, G | 1 |
| Gaviano, M | 1 |
| Carboni, R | 1 |
| Ottonello, G | 1 |
| Crisafulli, M | 1 |
| Fanos, V | 1 |
| Dessì, A | 1 |
| Cianci, A | 1 |
| Panella, M | 1 |
| Fichera, M | 1 |
| Falduzzi, C | 1 |
| Bartolo, M | 1 |
| Caruso, S | 1 |
| Bizzarri, M | 1 |
| Benvenga, S | 1 |
| D'Anna, R | 3 |
| Lanzone, A | 1 |
| Soulage, C | 1 |
| Di Renzo, GC | 1 |
| Hod, M | 1 |
| Cavalli, P | 1 |
| Chiu, TT | 1 |
| Kamenov, ZA | 1 |
| Bevilacqua, A | 1 |
| Carlomagno, G | 1 |
| Gerli, S | 1 |
| Oliva, MM | 1 |
| Devroey, P | 1 |
| Paul, C | 1 |
| Laganà, AS | 1 |
| Maniglio, P | 1 |
| Triolo, O | 1 |
| Brady, DM | 1 |
| Ontiveros, AE | 1 |
| Roberts, RP | 1 |
| Saade, MM | 1 |
| Maeba, R | 1 |
| Hara, H | 1 |
| Ishikawa, H | 1 |
| Hayashi, S | 1 |
| Yoshimura, N | 1 |
| Kusano, J | 1 |
| Takeoka, Y | 1 |
| Yasuda, D | 1 |
| Okazaki, T | 1 |
| Kinoshita, M | 1 |
| Teramoto, T | 1 |
| Heikkilä, O | 1 |
| Lundbom, N | 1 |
| Timonen, M | 1 |
| Groop, PH | 1 |
| Heikkinen, S | 1 |
| Mäkimattila, S | 1 |
| Giordano, D | 2 |
| Corrado, F | 2 |
| Santamaria, A | 2 |
| Quattrone, S | 1 |
| Pintaudi, B | 2 |
| Di Benedetto, A | 1 |
| Haley, AP | 1 |
| Gonzales, MM | 1 |
| Tarumi, T | 1 |
| Miles, SC | 1 |
| Goudarzi, K | 1 |
| Tanaka, H | 1 |
| Fujitaka, K | 1 |
| Otani, H | 1 |
| Jo, F | 1 |
| Jo, H | 1 |
| Nomura, E | 1 |
| Iwasaki, M | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Kawamori, R | 1 |
| Interdonato, ML | 1 |
| Vieste, GD | 1 |
| Benedetto, AD | 1 |
| Nordio, M | 1 |
| Proietti, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial[NCT04273256] | Phase 2/Phase 3 | 226 participants (Anticipated) | Interventional | 2020-02-11 | Recruiting | ||
| Effect of Myoinositol on Serum Asprosin Levels in Pregnant Women[NCT05943158] | 40 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes[NCT02097069] | 80 participants (Anticipated) | Interventional | 2014-04-30 | Not yet recruiting | |||
| Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity[NCT03283813] | Phase 4 | 60 participants (Anticipated) | Interventional | 2018-02-05 | Recruiting | ||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Effects of Myo-inositol Plus Melatonin in Perimenopausal Women[NCT01325389] | 0 participants | Interventional | Recruiting | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for inositol and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Cyclitols; Diabetes Mellitus, Type 2; Dietary Supplements; Human | 2019 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycys | 2016 |
7 trials available for inositol and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Blood Glucose; Body Mass Index; Breast Neoplasms; Caloric Restriction; Cholesterol | 2013 |
Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Hyperlipidemias; Inositol; Li | 2008 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; | 2011 |
[Evidence demonstrating the effect of voglibose for the prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese subjects with inpaired glucose tolerance].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hy | 2011 |
One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Caloric Restriction; Cholesterol, HDL; Dietary Suppl | 2012 |
The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Topics: Adolescent; Adult; Analysis of Variance; Biomarkers; Drug Combinations; Female; Humans; Inositol; Me | 2012 |
10 other studies available for inositol and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Inositols: reflections on how to choose the appropriate one for PCOS.
Topics: Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycystic Ovary Syndrome; Vitamin | 2020 |
An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Clindamycin; Dietary Supplem | 2020 |
Vascular and metabolic profiles in offspring born to pregnant mice with metabolic syndrome treated with inositols.
Topics: Animals; Biomarkers; Drug Administration Schedule; Female; Hypertension; Inositol; Male; Metabolic S | 2019 |
Urinary metabolomics (GC-MS) reveals that low and high birth weight infants share elevated inositol concentrations at birth.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Gas Chromatography-Mass Spectrometry; Ge | 2014 |
d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Inositol; Menstruation Disturbances; M | 2015 |
Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Topics: Congenital Abnormalities; Diabetes, Gestational; Female; Humans; Inositol; Insulin Resistance; Metab | 2015 |
The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity.
Topics: Animals; Biomarkers; Blood Glucose; Dietary Supplements; Disease Models, Animal; Female; Gastric Inh | 2016 |
Risk for metabolic syndrome predisposes to alterations in the thalamic metabolism.
Topics: Adult; Anthropometry; Aspartic Acid; Blood Glucose; Choline; Creatine; Diabetes Mellitus, Type 2; Hu | 2008 |
Elevated cerebral glutamate and myo-inositol levels in cognitively normal middle-aged adults with metabolic syndrome.
Topics: Adult; Brain Chemistry; Cognition Disorders; Disease Progression; Female; Glutamic Acid; Humans; Ino | 2010 |